Clinical Trials Browser

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gallbladder Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05325866 2026-02-04

FORTITUDE-301

Phase 1/2 Completed

260 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

796 enrolled

BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04421820 2026-01-27

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Phase 1/2 Recruiting

220 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05874414 2026-01-22

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Phase 1/2 Recruiting

74 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06399757 2026-01-07

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Phase 1/2 Recruiting

100 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Adenocarcinoma, Mucinous, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07291947 2025-12-18

PULSAR Combined With Immunotherapy and Chemotherapy

Phase 1/2 Recruiting

60 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Not yet recruiting

160 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Phase 1/2 Terminated

8 enrolled 12 charts

GastrointestinalGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05220722 2025-10-23

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Phase 1/2 Terminated

23 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase 1/2 Completed

53 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05253053 2025-06-12

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Phase 1/2 Completed

84 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms